Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHidalgo Gómez, Gloria
dc.contributor.authorPalacio-Garcia, Carles
dc.contributor.authorMartínez-Morgado, Noemi
dc.contributor.authorOrtega Blanco, Margarita
dc.contributor.authorTazon-Vega, Barbara
dc.contributor.authorSaumell, Silvia
dc.contributor.authorMurillo-Sanjuán, Laura
dc.contributor.authorVELASCO, PABLO
dc.contributor.authorMurciano, Thais
dc.contributor.authorDiaz de Heredia, Cristina
dc.contributor.authorBosch, Francesc
dc.contributor.authorNavarro Garces, Victor
dc.date.accessioned2025-07-03T07:55:44Z
dc.date.available2025-07-03T07:55:44Z
dc.date.issued2025-04
dc.identifier.citationHidalgo-Gómez G, Tazón-Vega B, Palacio C, Saumell S, Martínez-Morgado N, Navarro V, et al. How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia. Ann Hematol. 2025 Apr;104:2387-402.
dc.identifier.issn1432-0584
dc.identifier.urihttp://hdl.handle.net/11351/13341
dc.descriptionAcute lymphoblastic leukemia; Genetic diagnosis; Multiple-technique approach
dc.description.abstractThis study investigated the importance of comprehensive genetic diagnosis in pediatric B-cell acute lymphoblastic leukemia (B-ALL). We analyzed 175 B-ALL employing karyotyping, FISH, MLPA, targeted next-generation sequencing (t-NGS), and Optical Genome Mapping (OGM). This approach achieved an 83% classification rate, identifying 17 distinct genetic subtypes. Specifically, within B-other subtype, seven different subgroups were identified (ZNF384, IGH, DUX4, NUTM1 rearrangements, PAX5 alterations, PAX5 P80R, and IKZF1 N159Y). Secondary genetic alterations were observed, with copy number alterations (CNA) present in 60% of cases and mutations detected in 70.6%. While these alterations exhibited specific associations with certain genetic subtypes, CNAs did not appear to significantly impact the prognosis within these genetic groups. HeH, ETV6::RUNX1, ZNF384-r, and PAX5 P80R exhibited excellent outcomes, contrasting with the poor prognoses observed in KMT2A-r, hypodiploidy, and CRLF2-r (5-year overall OS were 50%, 50%, and 52%, respectively). These findings underscore the value of integrated genetic diagnostics for accurate subtyping, risk stratification, and guiding personalized treatment in pediatric B-ALL. Therefore, optimizing diagnostic workflows for routine clinical practice is crucial. Our study confirms the utility of conventional techniques (karyotyping and FISH), combined with t-NGS and OGM, for comprehensive genetic diagnosis.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesAnnals of Hematology;104
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCromosomes humans - Anomalies - Diagnòstic
dc.subjectLeucèmia limfoblàstica - Diagnòstic
dc.subjectLeucèmia limfoblàstica - Aspectes genètics
dc.subjectInfants
dc.subject.meshPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.mesh/diagnosis
dc.subject.meshGenetic Testing
dc.subject.meshChild
dc.titleHow to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s00277-024-06151-7
dc.subject.decsleucemia-linfoma linfoblástico de células B precursoras
dc.subject.decs/diagnóstico
dc.subject.decspruebas genéticas
dc.subject.decsniño
dc.relation.publishversionhttps://doi.org/10.1007/s00277-024-06151-7
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Hidalgo Gómez G] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Unit of Biological Anthropology, Department of Animal Biology, Plant Biology, and Ecology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Tazón-Vega B, Palacio C, Saumell S, Martínez-Morgado N, Bosch F, Ortega M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Navarro V] Oncology Data Science (ODysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Murillo L, Velasco P, Murciano T, Díaz de Heredia C] Servei d’Hematologia i Oncologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid39843811
dc.identifier.wos001401855200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record